This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Purohit, A. Articles by Reed, M. J. Search for Related Content PubMed PubMed Citation Articles by Purohit, A. Articles by Reed, M. J.

In Vivo Activity of 4-Methylcoumarin-7-O-Sulfamate, a Nonsteroidal, Nonestrogenic Steroid Sulfatase Inhibitor¹

Unit of Metabolic Medicine, Imperial College School of Medicine at St. Mary's, London W2 1PG, United Kingdom [A. P., A. S., C. J. W., M. J. R.], and School of Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, United Kingdom [L. W. L. W., B. V. L. P.]

Steroid sulfatase regulates the formation of estrone from estrone sulfate (E1S) and dehydroepiandrosterone (DHA) from DHA sulfate. DHA can be converted to androstenediol, a steroid with potent estrogenic properties, and inhibition of steroid sulfatase activity is therefore an important therapeutic target. Because nonsteroidal steroid sulfatase inhibitors may offer some advantage for use in the treatment of breast cancer, 4-methylcoumarin-7-O-sulfamate (COUMATE) was synthesized and shown to be active in vitro. In this study, in vitro and in vivo techniques have been used to confirm that COUMATE, in contrast to the steroidal steroid sulfatase inhibitor estrone-3-O-sulfamate, is devoid of estrogenic activity. COUMATE did not stimulate the growth of MCF-7 breast cancer cells or uteri of ovariectomized rats, in contrast to estrone-3-O-sulfamate. COUMATE was orally active in vivo and after multiple dosing (10 mg/kg/day for 7 days) inhibited liver estrone sulfatase activity by 85%. Seven days after single or multiple dosing with COUMATE, liver estrone sulfatase activity was almost fully restored. Measurement of estrone sulfatase activity in WBCs revealed a degree of inhibition similar to that detected in liver samples. COUMATE was able to completely block the ability of E1S to stimulate uterine growth in ovariectomized rats. The development of a potent nonsteroidal, nonestrogenic steroid sulfatase inhibitor should allow the therapeutic potential of this type of therapy to be evaluated.

¹ This study was supported by the Cancer Research Campaign.

² Lister Institute Research Professor.

³ To whom requests for reprints should be addressed. Phone: 44-171-725-1738; Fax: 44-171-1725-1790.

Received 5/28/96. Accepted 8/29/96.

This article has been cited by other articles:

				M. J. Reed, A. Purohit, L. W. L. Woo, S. P. Newman, and B. V. L. Potter Steroid Sulfatase: Molecular Biology, Regulation, and Inhibition Endocr. Rev., April 1, 2005; 26(2): 171 - 202. [Abstract] [Full Text] [PDF]

				A. Purohit, L. W. L. Woo, B. V. L. Potter, and M. J. Reed In Vivo Inhibition of Estrone Sulfatase Activity and Growth of Nitrosomethylurea-induced Mammary Tumors by 667 COUMATE Cancer Res., July 1, 2000; 60(13): 3394 - 3396. [Abstract] [Full Text]

				T. Utsumi, N. Yoshimura, S. Takeuchi, J. Ando, M. Maruta, K. Maeda, and N. Harada Steroid Sulfatase Expression Is an Independent Predictor of Recurrence in Human Breast Cancer Cancer Res., January 1, 1999; 59(2): 377 - 381. [Abstract] [Full Text] [PDF]